Cosentyx (secukinumab) is a medication used to treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug is a biologic medication that works by blocking a protein called interleukin-17A, which is involved in the inflammatory response of the body.

According to the sources provided, Cosentyx has been approved by the FDA for use in children and adolescents with enthesitis-related arthritis and psoriatic arthritis [3]. The drug is available in an injectable form and can be used in children aged six years and older [2].

However, it is important to note that the use of Cosentyx in children should be closely monitored by a healthcare professional. The medication may increase the risk of infections, and the safety and efficacy of the drug have not been established in children with other inflammatory conditions [2].

In conclusion, Cosentyx has been approved by the FDA for use in children and adolescents with enthesitis-related arthritis and psoriatic arthritis. However, the use of the drug in children should be closely monitored by a healthcare professional due to potential risks. The safety and efficacy of the drug have not been established in children with other inflammatory conditions.

Sources:
[2] https://www.cosentyx.com/pediatric-psoriasis
[3] https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis